TAK-779 was the first non-peptide antagonist for C-C chemokine receptor type 5 (CCR5) receptor that effectively blocks the cell entry of R5-type HIV [1]. TAK-779 is also an antagonist of CCR2b and CXC chemokine receptor 3 (CXCR3) [2]. Treatment with TAK-779 reduced incidence and severity of experimental autoimmune encephalomyelitis due to reduced migration of inflammatory cells into the CNS [3].

TAK-779 was the first non-peptide antagonist for C-C chemokine receptor type 5 (CCR5) receptor that effectively blocks the cell entry of R5-type HIV [1]. TAK-779 is also an antagonist of CCR2b and CXC chemokine receptor 3 (CXCR3) [2]. Treatment with TAK-779 reduced incidence and severity of experimental autoimmune encephalomyelitis due to reduced migration of inflammatory cells into the CNS [3].